Daniel Heng/X
Jun 2, 2025, 08:58
Daniel Heng: EV Prembrolizumab for metastatic bladder cancer
Daniel Heng, Head of Medical Oncology at the Arthur J.E. Child Comprehensive Cancer Centre in Calgary, Alberta, shared on X:
“EV Prembrolizumab for metastatic bladder cancer: CR rates are high and their duration of response long. Definitely the standard of care. CR patients had an average of 13 cycles of EV. Optimizing and learning about EV dosing and weaning in CR patients is important.”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Aug 18, 2025, 15:02
Aug 18, 2025, 14:54
Aug 18, 2025, 14:54
Aug 18, 2025, 14:47